23.11.2020 HAEMATO AG  DE000A289VV1

DGAP-News: HAEMATO AG: The sales of HAEMATO AG increased in the first nine months of 2020 by 23.8 % compared to the same period of the previous year to 175.6 million EUR


 

DGAP-News: HAEMATO AG / Key word(s): Quarter Results/9 Month figures
HAEMATO AG: The sales of HAEMATO AG increased in the first nine months of 2020 by 23.8 % compared to the same period of the previous year to 175.6 million EUR

23.11.2020 / 16:15
The issuer is solely responsible for the content of this announcement.


November 23, 2020

The sales of HAEMATO AG increased in the first nine months of 2020 by 23.8 % compared to the same period of the previous year to 175.6 million EUR.

HAEMATO AG, Berlin (ISIN: DE000A289VV1), achieved IFRS group sales of EUR 59.8 million in the third quarter of 2020 (previous year: EUR 47.8 million). For the observed period from January to September 2020, sales totaled EUR 175.6 million (previous year: EUR 141.8 million). Sales were thus 23.8 % above sales in the first nine months of 2019. EBITDA is 3.1 million euros (previous year: 1.5 million euros).

Despite the pandemic, HAEMATO AG was able to largely maintain its business processes with numerous organizational measures and to guarantee a constant supply of goods to its customers.

As one of the leading providers of specialty pharmaceuticals, the HAEMATO Group benefits from competition in the primary healthcare market. The specialization in medicines for the treatment of chronic diseases and for individual therapies leads us to expect a potential for growth in the future due to demographic development.

About HAEMATO:

HAEMATO AG, founded in 1993, is a pharmaceutical company focusing on the growing mar-kets of high-priced specialty pharmaceuticals in the indication areas of oncology and HIV as well as other chronic diseases.

HAEMATO AG is listed in the Basic Board (Open Market) of the Frankfurt Stock Exchange. Key figures on the HAEMATO AG share:
Subscribed capital: EUR 2,286,715
Listed class of shares: bearer ordinary shares
ISIN: DE000A289VV1
WKN: A289VV
Stock exchange code: HAEK




Contact:
HAEMATO AG, Investor Relations
Telefon: +49 (0)30 897 30 86 70
[email protected]


23.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: HAEMATO AG
Lilienthalstraße 5c
12529 Schönefeld
Germany
Phone: +49 (0)30 897 30 86 70
Fax: +49 (0)30 897 30 86 79
E-mail: [email protected]
Internet: www.haemato.ag
ISIN: DE000A289VV1
WKN: A289VV
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate Exchange
EQS News ID: 1150031

 
End of News DGAP News Service

1150031  23.11.2020 

fncls.ssp?fn=show_t_gif&application_id=1150031&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2016 2017 2018 2019 2020 2021 2022e
Umsatzerlöse1 275,61 289,86 274,12 197,84 238,33 285,04 270,00
EBITDA1,2 15,25 11,27 9,96 1,90 3,31 12,64 0,00
EBITDA-Marge3 5,53 3,89 3,63 0,96 1,39 4,43 0,00
EBIT1,4 13,44 9,42 8,50 -18,68 1,63 11,16 9,00
EBIT-Marge5 4,88 3,25 3,10 -9,44 0,68 3,92 3,33
Jahresüberschuss1 11,04 6,98 6,28 -1,17 -4,83 6,53 0,00
Netto-Marge6 4,01 2,41 2,29 -0,59 -2,03 2,29 0,00
Cashflow1,7 12,75 -8,35 0,56 -2,76 14,67 14,05 0,00
Ergebnis je Aktie8 5,30 3,20 2,70 -0,50 -1,02 1,35 1,02
Dividende8 3,00 3,00 1,00 0,00 0,00 1,10 0,50
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2021 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Harry Haseloff

INVESTOR-INFORMATIONEN
©boersengefluester.de
Haemato
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A289VV 19,700 - 103,02
KGV 2023e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
13,13 15,41 0,84 8,85
KBV KCV KUV EV/EBITDA
0,74 7,33 0,36 7,28
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 1,10 5,58 12.07.2022
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
25.05.2022 25.08.2022 17.11.2022 17.05.2022
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-6,40% -15,13% -17,57% -28,88%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu HAEMATO AG  ISIN: DE000A289VV1 können Sie bei DGAP abrufen


Gesundheit , A289VV , HAEK , XETR:HAE